NCT07710690招募中1 期
A Clinical Trial Evaluating the Tolerability, Safety, and Preliminary Efficacy of NRG-103 Injection in Patients With Recurrent or Progressive High-grade Glioma
Neuregen Therapeutics Co., Ltd.3 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2026年7月9日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 24
- 试验地点
- 3
- 主要终点
- AE/SAE/AESI
研究概览
简要总结
The primary objective of this study is to determine the safe dose range of NRG-103 in patients and to recommend the dosage for subsequent treatment, while also evaluating the preliminary efficacy and tolerability of the product.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Willing to voluntarily participate in the study, able to sign the Informed Consent Form (ICF), and willing to comply with the procedures specified in the study protocol.
- •Age ≥18 years, regardless of gender.
- •Participants must have a prior diagnosis of World Health Organization (WHO) Grade 3 or 4 glioma, according to the WHO (2021) classification criteria. A pathology report containing histopathological typing and necessary molecular pathology test results must be provided; this report will serve as sufficient histological documentation for study enrollment.
- •Patients must have exhausted standard anti-tumor therapies or be intolerant to standard treatments (including chemoradiotherapy, targeted therapy, or immunotherapy), as evidenced by the occurrence of Grade ≥3 non-hematologic toxicities or Grade 4 hematologic toxicities. There must be definitive evidence of recurrent or progressive glioma on magnetic resonance imaging (MRI) scans (assessed according to the RANO 2.0 criteria), with no recognized effective treatment options remaining. If MRI scans are inconclusive regarding tumor recurrence or progression, surgery/biopsy is recommended; however, surgery/biopsy is not required if the investigator determines that the combination of the imaging report and clinical manifestations is sufficient to indicate tumor recurrence or progression.
排除标准
- •Patients with known or suspected hypersensitivity to any components of the investigational medicinal product or to contrast agents.
- •Patients with contraindications to magnetic resonance imaging (MRI) scanning, including but not limited to: cardiac pacemakers, epicardial pacing leads, surgical and/or aneurysm clips, shrapnel, metal prostheses, potentially magnetically active implants, metallic foreign bodies in the eye, and non-removable metal dentures.
- •Patients with a history of prior gene therapy or oncolytic virus therapy.
- •Patients who have participated in other clinical trials and received other investigational drugs within 28 days prior to the first administration of NRG-
- •5, Patients who have received anti-tumor vaccines or other immunomodulatory agents (e.g., interferons, interleukin-2, thymosin, lentinan, etc.) within 4 weeks prior to enrollment. Patients who have received or are scheduled to receive live attenuated or recombinant vaccines within 4 weeks; or patients who have received or are scheduled to receive inactivated vaccines within 1 week.
结局指标
主要结局
AE/SAE/AESI
时间窗: 2 year
DLT
时间窗: 8 weeks
次要结局
- PFS6(2 years)
研究者
研究点 (3)
Loading locations...
相似试验
尚未招募
1 期
A Study on the Safety and Tolerability of Universal STAR-T Cell Therapy for Multiple Sclerosis.Multiple Sclerosis (MS)NCT07523100Daishi Tian24
招募中
1 期
Clinical Study of O&D-001 Injection in the Treatment of Relapsed or Refractory Multiple MyelomaNCT07369895O&D BioTech Group CO., Limited18
已完成
1 期
Phase IIT Trial of SNA009GPA33Colorectal CancerNCT07597759SmartNuclide Biopharma12
招募中
1 期
KXV01 Injection in Patients With Advanced Solid Tumor (Including Osteosarcoma and Sarcoma)Advanced Solid TumorsNCT07596693TCRx Therapeutics Co.Ltd30
招募中
1 期
KSV01 Injection for the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaDiffuse Large B Cell Lymphoma (DLBCL)NCT07260812TCRx Therapeutics Co.Ltd18